
Egetis Therapeutics Q2 - Eventful quarter

Redeye returns with an updated view of Egetis Therapeutics following the Q2 report and recent events in the company. We mostly reiterate our stance to the company but have made some adjustments based on the TRIAC II results and revised assumptions for the ReTRIACt trial.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Egetis Therapeutics Q2 - Eventful quarter](#)